Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 September 2022 | Story André Damons | Photo Jack once productions
The three directors of Epicutis Skincare
All smiles. The three directors of Epicutis Skincare; Dr Maanda Tshikororo, Chief Marketing Officer; Dr Lehlohonolo Makhakhe, Chief Executive officer and primary formulation scientist; and Mrs Mantwa Makhakhe, Chief Operating Officer, showing of some of their new skincare products

A senior lecturer and specialist in the Department of Dermatology at the University of the Free State (UFS) and his two associates, who are also postgraduate students at the university, have realised their dream when they launch their skincare company next month.
 

Dr Lehlohonolo Makhakhe, a full-time medical specialist (dermatologist), Dr Maanda Tshikororo, a medical doctor and a postgraduate student in the Department of Psychiatry, and Mrs Mantwa Makhakhe, who holds a BCom Economics degree and is currently completing her postgraduate diploma in financial planning, are the directors of Epicutis Skincare. Dr Makhakhe, who is also a PhD candidate registered with UFS, is the Chief Executive Officer and primary formulation scientist for the company, while Dr Tshikororo is the Chief Marketing Officer and Mrs Makhakhe the Chief Operating Officer.

The company is launching on 22 October 2022.

Narrowing the gap between treating skin ailments and manufacturing skincare products

According to Dr Makhakhe, who published the very first comprehensive African atlas on skin diseases commonly seen in the African setting,The African Atlas, synopsis and practical guide to clinical dermatology, says Epicutis is a company which will produce a range of personal skincare products. The range will comprise of products such as body lotions, body creams, petroleum jelly and a night cream. Since becoming a dermatologist, he has always wished to narrow the gap between being a clinician treating skin ailments and being involved in manufacturing skincare products.

“Creating products as a dermatologist has great benefits, because the products are created from a clinician’s perspective, with more intentional results. All ingredients used were carefully selected for their specific and scientifically proven benefits, they were then tested for stability in terms of viscosity, pH, microbiology in association with the South African Institute of Dermatology and other third parties,” says Dr Makhakhe. 

Ecstatic about the upcoming launch

Dr Tshikororo says this has been an adventure they have always thought of undertaking. “We finally reached a point of shifting from the comfort of dreaming about it, to taking action.” 

“We hope our company will play a notable role in creating permanent employment for the youth, and also have an impact on the growth of the economy of the Free State province and that of the country as well,” says Mrs Makhakhe. 
The three directors are ecstatic about the upcoming launch of their products, and optimistic that there is enough room for new, affordable, locally manufactured skincare products that are suitable for all family members.  

All products will be available at major retailers soon after the launch. Further information is available at the official website

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept